Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ARCT Arcturus Therapeutics Ltd.

Post-Market Trading 03-24 16:28:24 EDT

13.27

+0.39

+3.03%

盘后13.05

-0.22-1.66%

16:24 EDT

High13.31	Low12.85	Vol241.06K
Open12.95	D1 Closing12.88	Amplitude3.57%
Mkt Cap359.88M	Tradable Cap329.54M	Total Shares27.12M
T/O3.17M	T/O Rate0.97%	Tradable Shares24.83M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ARCT","market":"US","secType":"STK","nameCN":"Arcturus Therapeutics Ltd.","latestPrice":13.27,"timestamp":1742846400000,"preClose":12.88,"halted":0,"volume":241059,"hourTrading":{"tag":"盘后","latestPrice":13.05,"preClose":13.27,"latestTime":"16:24 EDT","volume":5641,"amount":74844.652616,"timestamp":1742847867982},"delay":0,"floatShares":24833621,"shares":27119823,"eps":-3,"marketStatus":"Post-Market Trading","change":0.39,"latestTime":"03-24 16:28:22 EDT","open":12.95,"high":13.305,"low":12.845,"amount":3166057.3351680003,"amplitude":0.035714,"askPrice":13.3,"askSize":1,"bidPrice":13.05,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1742860800000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":12.88,"preHourTrading":{"tag":"盘前","latestPrice":13.01,"preClose":12.88,"latestTime":"09:29 EDT","volume":58,"amount":754.58,"timestamp":1742822970079},"postHourTrading":{"tag":"盘后","latestPrice":13.05,"preClose":13.27,"latestTime":"16:24 EDT","volume":5641,"amount":74844.652616,"timestamp":1742847867982},"volumeRatio":0.624448,"impliedVol":0.7464,"impliedVolPercentile":0.424},"requestUrl":"/m/hq/s/ARCT","defaultTab":"news","newsList":[{"id":"2518080720","title":"Despite Revenue Setback, Arcturus Therapeutics (ARCT) Vaccine Breakthroughs Fuel Optimism","url":"https://stock-news.laohu8.com/highlight/detail?id=2518080720","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518080720?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 11:35","pubTimestamp":1741750514,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics ($ARCT) had a challenging fourth quarter, with revenue and earnings falling short of analyst expectations. Their annual reven...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/despite-revenue-setback-arcturus-therapeutics-arct-vaccine-breakthroughs-fuel-optimism?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/despite-revenue-setback-arcturus-therapeutics-arct-vaccine-breakthroughs-fuel-optimism?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARCT"],"gpt_icon":0},{"id":"2518275020","title":"Arcturus Therapeutics Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2518275020","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518275020?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 22:50","pubTimestamp":1741618200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARCT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2025 10:50 ET (14:50 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ARCT"],"gpt_icon":0},{"id":"2518230558","title":"Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), Halozyme (HALO) and Arcturus Therapeutics (ARCT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2518230558","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518230558?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 08:21","pubTimestamp":1741566079,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Protagonist Therapeutics (PTGX – Research Report), H...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-protagonist-therapeutics-ptgx-halozyme-halo-and-arcturus-therapeutics-arct?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-protagonist-therapeutics-ptgx-halozyme-halo-and-arcturus-therapeutics-arct?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HALO","PTGX","ARCT","LU0053671581.USD","BK4139","BK4137","HCSG"],"gpt_icon":0},{"id":"2518786283","title":"Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Are Cutting Their Estimates: Here's What You Need To Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2518786283","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518786283?lang=en_us&edition=full_marsco","pubTime":"2025-03-09 21:31","pubTimestamp":1741527083,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics Holdings Inc.  missed earnings with its latest annual results, disappointing overly-optimistic forecasters. Unfortunately, Arcturus Therapeutics Holdings delivered a serious earnings miss. Revenues of US$152m were 13% below expectations, and statutory losses ballooned 27% to US$3.00 per share. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.See our latest analysis for Arcturus Therapeutics Holdings. The most important thing to note is the forecast of increased losses next year, suggest","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-holdings-inc-nasdaq-133123566.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","TQQQ","TSYW.SI","LU2210149790.SGD","BK4588","BK4112","BK4585","MNQmain","LU2210150020.SGD","LU2095319765.USD","PSQ","ARCT","IE00BGHQF748.EUR","IE00B64PRP62.GBP","NVIW.SI","QLD","SQQQ","IE00BKPKM429.USD","NDAQ","NQmain","USJW.SI","BK4139","USAW.SI","IE00B3QW5Z07.USD","QID"],"gpt_icon":1},{"id":"2517459163","title":"Arcturus Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2517459163","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517459163?lang=en_us&edition=full_marsco","pubTime":"2025-03-08 01:44","pubTimestamp":1741369440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARCT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 07, 2025 12:44 ET (17:44 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARCT","LENZ"],"gpt_icon":0},{"id":"2517345814","title":"Q4 2024 Arcturus Therapeutics Holdings Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2517345814","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517345814?lang=en_us&edition=full_marsco","pubTime":"2025-03-08 00:16","pubTimestamp":1741364177,"startTime":"0","endTime":"0","summary":"Neda Safarzadeh; Vice President and Head of Investor Relations, Public Relations, and Marketing; Arcturus Therapeutics Holdings Inc. Joseph Payne; President, Chief Executive Officer, Director; Arcturus Therapeutics Holdings Inc. Andrew Sassine; Chief Financial Officer, Director; Arcturus Therapeutics Holdings Inc. Padmanabh Chivukula; Chief Operating Officer, Chief Scientific Officer; Arcturus Therapeutics Holdings Inc. Thank you for holding, ladies and gentlemen. We thank you for your patience and ask that you please continue to hold. Good day, everyone, and welcome to Arcturus Therapeutics fourth and full-year 2024 earnings call.  Please note, today's call will be recorded  It is now my pleasure to turn the conference over to Neda Safarzadeh, Vice President and Head of Investor Relations, Public Relations, and Marketing. Neda, please go ahead.Thank you, Neda. It's good to be with you again, everybody. We look forward to providing our updates today on our quarterly investor call. I wi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-arcturus-therapeutics-holdings-161617041.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARCT","LENZ"],"gpt_icon":0},{"id":"2517362594","title":"Arcturus Therapeutics Holdings Inc : Canaccord Genuity Cuts Target Price to $68 From $74","url":"https://stock-news.laohu8.com/highlight/detail?id=2517362594","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517362594?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 22:23","pubTimestamp":1741357404,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nFWN3PQ12A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARCT","BK4139"],"gpt_icon":0},{"id":"2517171608","title":"Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Call Highlights: Navigating ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2517171608","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517171608?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 15:17","pubTimestamp":1741331836,"startTime":"0","endTime":"0","summary":"Revenue : $152.3 million, a decrease from $166.8 million in 2023.Revenue : $22.8 million, down from $30.9 million in Q4 2023.Net Loss : Approximately $80.9 million or $3 per diluted share.Total Operating Expenses : $56.2 million, compared to $49.1 million in Q4 2023.Research and Development Expenses : $43.8 million, up from $36.6 million in Q4 2023.General and Administrative Expenses : $52.8 million, slightly down from $52.9 million in 2023.Cash and Cash Equivalents : $293.9 million, down from $348.9 million at the end of 2023.Cash Burn : Approximately $55 million, compared to $45 million in 2023.Gross Profit from KOSTAIVE Sales : Approximately $28 million.GuruFocus has detected 4 Warning Signs with ARCT.Arcturus Therapeutics Holdings Inc  received European Commission approval for KOSTAIVE, the world's first approved self-amplifying mRNA COVID-19 vaccine.Arcturus Therapeutics Holdings Inc  achieved a total of approximately $473.1 million in upfront payments and milestones from CSL as o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-holdings-inc-arct-071716440.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARCT"],"gpt_icon":0},{"id":"2517178708","title":"U.S. RESEARCH ROUNDUP- Adobe, Tesla, Victoria's Secret","url":"https://stock-news.laohu8.com/highlight/detail?id=2517178708","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517178708?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 15:04","pubTimestamp":1741331083,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Adobe, Tesla, Victoria's Secret March 7 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adobe, Te","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nL3N3PQ0LA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1035775433.USD","LU0456855351.SGD","LU2095319765.USD","STZ","LU0820561818.USD","LU2210149790.SGD","LU0792757196.USD","ADBE","BURL","SG9999002232.USD","LU0162691827.USD","LU0321505868.SGD","F","MLNK","BK4539","TSLA","GMS","LU0072461881.USD","LU1815333072.USD","TSYW.SI","COOK","LU0106261372.USD","SG9999003800.SGD","OLLI","LU2063271972.USD","LU0889566641.SGD","LU0477156953.USD","GT","ARCT","LU0234570918.USD","LU0198837287.USD","GM","LU0345769631.USD","VSCO","LU2108987350.USD","PRTH","SGXZ81514606.USD","LU0170899867.USD","BJ","LU0985481810.HKD","HRZN","RYN","LU0234572021.USD","W","BK4596","BK4119","LU1496350502.SGD"],"gpt_icon":1},{"id":"2517012336","title":"Arcturus Therapeutics Holdings Inc : Leerink Partners Cuts Target Price to $65 From $70","url":"https://stock-news.laohu8.com/highlight/detail?id=2517012336","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517012336?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 11:53","pubTimestamp":1741319612,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nFWN3PP1CT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARCT","BK4139"],"gpt_icon":0},{"id":"2517694143","title":"Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2517694143","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517694143?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 06:15","pubTimestamp":1741299304,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics  came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -226.47%. A quarter ago, it was expected that this pharmaceutical company would post a loss of $0.70 per share when it actually produced a loss of $0.26, delivering a surprise of 62.86%.Arcturus Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $22.77 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 60.60%. This compares to year-ago revenues of $33.99 million. The company has topped consensus revenue estimates two times over the last four quarters.Arcturus Therapeutics shares have lost about 5.4% since the beginning of the year versus the S&P 500's decline of -0.7%.While Arcturus Therapeutics has underperformed ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-arct-reports-q4-221504874.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARCT"],"gpt_icon":0},{"id":"2517116470","title":"Arcturus Therapeutics Holdings Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2517116470","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517116470?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 06:01","pubTimestamp":1741298480,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics Holdings Inc reports results for the quarter ended December 31 - Earnings SummaryArcturus Therapeutics Holdings Inc ARCT.OQ reported a quarterly adjusted loss of $1.11 per share ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nL5N3PP2HU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARCT"],"gpt_icon":0},{"id":"2517392116","title":"Arcturus Therapeutics Shares Down  About 7% at $14.86 After the Bell Following Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2517392116","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517392116?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 05:52","pubTimestamp":1741297953,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nL2N3PP1BJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARCT"],"gpt_icon":0},{"id":"2517311542","title":"Arcturus Therapeutics: Q4 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=2517311542","media":"Associated Press Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517311542?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 05:26","pubTimestamp":1741296387,"startTime":"0","endTime":"0","summary":"SAN DIEGO  — SAN DIEGO  — Arcturus Therapeutics  on Thursday reported a loss of $30 million in its fourth quarter.On a per-share basis, the San Diego-based company said it had a loss of $1.11.The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 34 cents per share.The pharmaceutical company posted revenue of $22.8 million in the period, which also fell short of Street forecasts. Four analysts surveyed by Zacks expected $57.8 million.For the year, the company reported that its loss widened to $80.9 million, or $3 per share. Revenue was reported as $152.3 million.Arcturus Therapeutics shares have fallen roughly 6% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $15.97, a decrease of 58% in the last 12 months.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-q4-earnings-snapshot-212627046.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","ARCT"],"gpt_icon":0},{"id":"2517175118","title":"Arcturus Therapeutics Q4 2024 GAAP EPS $(1.11) Misses $(0.44) Estimate, Sales $22.800M Miss $44.650M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2517175118","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517175118?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 05:03","pubTimestamp":1741295017,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.44) by 152.27 percent. This is a 246.88 percent decrease over losses of $(0.32) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44179256/arcturus-therapeutics-q4-2024-gaap-eps-1-11-misses-0-44-estimate-sales-22-800m-miss-44-650m-estimat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ARCT"],"gpt_icon":0},{"id":"2517118623","title":"BRIEF-Arcturus Therapeutics Q4 Collaboration Revenue USD 21 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2517118623","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517118623?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 05:01","pubTimestamp":1741294905,"startTime":"0","endTime":"0","summary":"BRIEF-Arcturus Therapeutics Q4 Collaboration Revenue USD 21 Million\n\n\nMar 06 (Reuters) - Arcturus Therapeutics Q4 net income USD -30.005 million vs. IBES estimate USD -15 million.\n\nQ4 operating expenses USD 56.16 million\nQ4 operating income USD -33.394 million vs. IBES estimate USD -17.4 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nPLX73E47F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARCT"],"gpt_icon":0},{"id":"2517185501","title":"Arcturus Therapeutics Q4 Net Income USD -30.005 Million VS. Ibes Estimate USD -15 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2517185501","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517185501?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 05:01","pubTimestamp":1741294860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nPLX73E47F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARCT","BK4139"],"gpt_icon":0},{"id":"2517118607","title":"Arcturus Therapeutics Holdings Inc -Qtrly Shr Loss $1.11","url":"https://stock-news.laohu8.com/highlight/detail?id=2517118607","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517118607?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 05:01","pubTimestamp":1741294860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nPLX73E47F:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARCT","BK4139"],"gpt_icon":0},{"id":"2517111856","title":"Arcturus Therapeutics Q4 Collaboration Revenue USD 21 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2517111856","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517111856?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 05:01","pubTimestamp":1741294860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nPLX73E47F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARCT","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arcturusrx.com","stockEarnings":[{"period":"1week","weight":-0.0852},{"period":"1month","weight":-0.2564},{"period":"3month","weight":-0.168},{"period":"6month","weight":-0.3751},{"period":"1year","weight":-0.6112},{"period":"ytd","weight":-0.241}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":-0.0799},{"period":"3month","weight":-0.046},{"period":"6month","weight":-0.0075},{"period":"1year","weight":0.08},{"period":"ytd","weight":-0.0377}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.073454},{"month":2,"riseRate":0.5,"avgChangeRate":0.009833},{"month":3,"riseRate":0.25,"avgChangeRate":-0.038804},{"month":4,"riseRate":0.545455,"avgChangeRate":0.101832},{"month":5,"riseRate":0.636364,"avgChangeRate":0.1056},{"month":6,"riseRate":0.583333,"avgChangeRate":0.023074},{"month":7,"riseRate":0.583333,"avgChangeRate":0.109538},{"month":8,"riseRate":0.5,"avgChangeRate":0.045801},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.063785},{"month":10,"riseRate":0.416667,"avgChangeRate":-0.046065},{"month":11,"riseRate":0.666667,"avgChangeRate":0.063018},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.062042}],"exchange":"NASDAQ","name":"Arcturus Therapeutics Ltd.","nameEN":"Arcturus Therapeutics Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Arcturus Therapeutics Ltd.(ARCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Arcturus Therapeutics Ltd.,ARCT,Arcturus Therapeutics Ltd.股票,Arcturus Therapeutics Ltd.股票老虎,Arcturus Therapeutics Ltd.股票老虎国际,Arcturus Therapeutics Ltd.行情,Arcturus Therapeutics Ltd.股票行情,Arcturus Therapeutics Ltd.股价,Arcturus Therapeutics Ltd.股市,Arcturus Therapeutics Ltd.股票价格,Arcturus Therapeutics Ltd.股票交易,Arcturus Therapeutics Ltd.股票购买,Arcturus Therapeutics Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Arcturus Therapeutics Ltd.(ARCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}